MedTrace Logo

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

NCT00322270 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-08-15

No results posted yet for this study

Summary

To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.

Conditions

Interventions

DRUG

Alfimeprase

single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD

Sponsors & Collaborators

  • ARCA Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Susan Begelman, M.D. · ARCA Biopharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322270 on ClinicalTrials.gov